Upregulation of glucocorticoid receptor‐mediated glucose transporter 4 in enzalutamide‐resistant prostate cancer

Enzalutamide (Enz) is a second‐generation androgen receptor (AR) antagonist for castration‐resistant prostate cancer (CRPC) therapy, and it prolongs survival time in these patients. However, during Enz treatment, CRPC patients usually acquire resistance to Enz and often show cross‐resistance to othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshi, Seiji, Meguro, Satoru, Imai, Hitomi, Matsuoka, Yuta, Yoshida, Yuki, Onagi, Akihumi, Tanji, Ryo, Honda‐Takinami, Ruriko, Matsuoka, Kanako, Koguchi, Tomoyuki, Hata, Junya, Sato, Yuichi, Akaihata, Hidenori, Kataoka, Masao, Ogawa, Soichiro, Kojima, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088914/
https://www.ncbi.nlm.nih.gov/pubmed/33619826
http://dx.doi.org/10.1111/cas.14865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088914/
https://www.ncbi.nlm.nih.gov/pubmed/33619826
http://dx.doi.org/10.1111/cas.14865

Ejemplares similares